Identifying Side Effects of Some Drugs Used in Covid-19 Treatment

Aygün, İrfan; Kaya, Mehmet; Alhajj, Reda

doi:10.21203/rs.3.rs-40903/v1

Cited by 1 publication

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, we reduce the confounding effects of multiple drugs. Traditional pharmacosurveillance typically only concern how adverse events connected to specific therapy [32], however, our approach able to discover multiple drugs that may explain the change of reporting frequency during the pandemic, and control underlying variables in analysis. We consider two types of medication interference:…”

Section: Population-scale Adverse Event Model Of Patient Safetymentioning

confidence: 99%

“…Prior studies on adverse events have focused on laboratory environments, molecular characterization of drugs and target proteins, and limited clinical trial observations [26–29]. Studies examining reports of adverse events in the context of the pandemic were limited to very restricted pairs of drugs and adverse reactions, small numbers of reports, and narrow time ranges [30–32]. Further, such narrowly focused analyses can be confounded by historical biases in adverse event reporting and by mixing population groups that differ in their relative risks for clinical events.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Population-scale patient safety data reveal inequalities in adverse events before and during COVID-19 pandemic

Zhang

Sumathipala

Žitnik

2021

Preprint

View full text Add to dashboard Cite

Adverse patient safety events were associated with 110 thousand deaths in the U.S. alone in 2019. The COVID-19 pandemic has further challenged the ability of healthcare systems to ensure medication safety, and its effects on patient safety remain unknown. Here, we investigate negative outcomes associated with medication use before and during the pandemic. Using a dataset of 10,443,476 reports involving 3,624 drugs and 19,193 adverse events, we develop an algorithmic approach to analyze the pandemic’s impact on incidence of drug safety events by evaluating disproportional reporting relative to the pre-pandemic time, quantifying unexpected trends in clinical outcomes, and adjusting for drug interference. Among 64 adverse events identified by our analyses, we find 54 have increased incidence rates during the pandemic, even though reporting of adverse events has decreased by 4.4% overall. We find clinically relevant differences in drug safety outcomes between demographic groups. Comparing to male patients, women report 47.0% more distinct adverse events whose occurrence significantly increased during the pandemic relative to pre-pandemic levels. Out of 53 adverse events with the pre-pandemic gender gap, 33 have increased gap during the pandemic more than would have been expected had the pandemic not occurred. While musculoskeletal and metabolic side effects are disproportionately enriched in women during the pandemic, immune-related adverse events are enriched only in men. We also find the number of adverse events with a higher reporting ratio during the pandemic in adults is higher (16.8%) than in older patients (adjusted for population size). Our findings have implications for safe medication use and public health policy and highlight the role of variation in adverse events for improving patient safety during a public health emergency.

show abstract

Section: Population-scale Adverse Event Model Of Patient Safetymentioning

confidence: 99%